Microbot Medical Inc. (MBOT) Stock

Microbot Medical Inc. (MBOT) is a Healthcare stock trading at $1.51 (as of 2026-08-20), with a market capitalization of $101.75M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Microbot Medical Inc. develops robotic devices for minimally invasive procedures, including endoluminal surgery systems. Its portfolio includes micro-robotic technologies such as devices for cerebrospinal shunt cleaning and endovascular interventions, supported by an R&D pipeline and patent portfolio, with work conducted through technology collaboration with Stryker.

Understand Microbot Medical Inc.: how it makes money

Microbot Medical is a pre-clinical medical device company developing robotic endoluminal surgery devices and related technologies, including a Self Cleaning Shunt for hydrocephalus and normal pressure hydrocephalus, and a disposable robot for endovascular interventional procedures, built on its ViRob, TipCAT, CardioSert, and Liberty micro-robotic platforms.

Because Microbot Medical is pre-clinical, its profit model depends on successfully translating its multi-generation robotic device pipeline into products that can generate meaningful, recurring commercial revenue, rather than on current operating sales.

Business quality (Weak): Intellectual property and a defined product pipeline are clear, but the provided latest quarter shows reported revenue of 0.0B and an extreme operating loss, so near-term monetization risk appears high.

Bull case

  • Defined micro-robotic technology platforms and product pipeline: It is developing multiple robotic endoluminal surgery device concepts and a multi generation pipeline through ViRob, TipCAT, CardioSert, and Liberty.
  • Large disclosed IP base: The company reports 42 issued or allowed patents and 23 patent applications pending worldwide.

Bear case

  • Pre-clinical stage makes commercialization timing uncertain: The company describes itself as pre-clinical, which typically means products have not yet reached commercial use.
  • Very weak profitability in the latest reported period: For the period ended 2026-03-31, reported revenue is 0.0B, gross margin is 1.9%, and operating margin is -4114.3%.
Valuation — source: SEC EDGAR (first-party)
Price$1.51
Market Cap$101.75M
Price / Book1.48
FCF Yield-29.4%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD CAPITAL MANAGEMENT LLC ($7.01M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOHarel Gadot
Employees20
CountryUS
IPO Date1992-03-25

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Lucid Diagnostics Inc. (LUCD)
  • Femasys Inc. (FEMY)
  • KORU Medical Systems, Inc. (KRMD)
  • Apyx Medical Corporation (APYX)
  • Pulmonx Corporation (LUNG)
  • Sharps Technology, Inc. (STSS)
  • CVRx, Inc. (CVRX)
  • DarioHealth Corp. (DRIO)
MBOT earnings history · MBOT institutional & insider holders · MBOT KPIs & operating metrics · MBOT financials · MBOT investor presentations & press releases · MBOT SEC filings · MBOT peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.